Advances in cell and gene therapy最新文献_第7页

Update on Lymphoma classification: The 2016 revised World Health Organization Classification of Hematopoietic and Lymphoid Neoplasms 淋巴瘤分类更新：2016年修订的世界卫生组织造血和淋巴肿瘤分类

Advances in cell and gene therapy Pub Date : 2019-04-06 DOI: 10.1002/acg2.57

Ali Sakhdari, L. Jeffrey Medeiros

引用次数: 1

Does an increased probability of graft-vs-host disease improve the survival of patients with adult T-cell leukemia-lymphoma? A simulation analysis using a Markov model 移植物抗宿主病的可能性增加是否能提高成人t细胞白血病淋巴瘤患者的生存率?使用马尔可夫模型的仿真分析

Advances in cell and gene therapy Pub Date : 2019-03-31 DOI: 10.1002/acg2.56

Shigeo Fuji, Saiko Kurosawa, Yoshihiro Inamoto, Nobuaki Nakano, Yasuhiko Miyazaki, Kaname Miyashita, Michihiro Hidaka, Tetsuya Eto, Naoyuki Uchida, Asahi Ito, Yasushi Sawayama, Toshihiro Miyamoto, Junji Suzumiya, Atae Utsunomiya, Junya Kanda, Yoshiko Atsuta, Takahiro Fukuda, Koji Kato, Adult T-cell Leukemia-Working Group of Japan Society of Hematopoietic Cell Transplantation

{"title":"Does an increased probability of graft-vs-host disease improve the survival of patients with adult T-cell leukemia-lymphoma? A simulation analysis using a Markov model","authors":"Shigeo Fuji, Saiko Kurosawa, Yoshihiro Inamoto, Nobuaki Nakano, Yasuhiko Miyazaki, Kaname Miyashita, Michihiro Hidaka, Tetsuya Eto, Naoyuki Uchida, Asahi Ito, Yasushi Sawayama, Toshihiro Miyamoto, Junji Suzumiya, Atae Utsunomiya, Junya Kanda, Yoshiko Atsuta, Takahiro Fukuda, Koji Kato, Adult T-cell Leukemia-Working Group of Japan Society of Hematopoietic Cell Transplantation","doi":"10.1002/acg2.56","DOIUrl":"10.1002/acg2.56","url":null,"abstract":"Adult T-cell leukemia-lymphoma (ATL) is a peripheral T-cell lymphoma caused by human T-cell lymphotropic virus type I. Previous retrospective studies suggested the presence of graft-vs-ATL (GV-ATL) effects associated with acute graft-vs-host disease (GVHD), which suggests that intentional induction of acute GVHD to facilitate the efficacy of GV-ATL effects might reduce the risk of relapse and contribute to improved survival after allogeneic hematopoietic stem cell transplantation. However, it is impractical to conduct a prospective study to assess the benefit of intentional induction of acute GVHD. In a simulation analysis using a Markov model, we assessed the impact on overall survival (OS) of changing the probability of overall acute GVHD and severe acute GVHD. When the probability of grade III-IV acute GVHD changed from 0% to 100%, the expected 2-year OS rate changed from 57.0% to 21.8% (48.2% of baseline at 2 years). When the probability of all grades of acute GVHD changed from 0% to 100%, the expected 2-year OS rate changed from 48.2% to 49.5%. In conclusion, increasing the probability of overall acute GVHD was beneficial only when the proportion of grade III-IV acute GVHD was lower than that in the original data. Based on the simulation results, preventive management of grade III-IV acute GVHD is mandatory to achieve the clinical benefit associated with grade I-II GVHD.","PeriodicalId":72084,"journal":{"name":"Advances in cell and gene therapy","volume":"2 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/acg2.56","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50821827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

CAR-T cell therapy for non-Hodgkin lymphomas: A new treatment paradigm CAR-T细胞治疗非霍奇金淋巴瘤：一种新的治疗模式

Advances in cell and gene therapy Pub Date : 2019-03-28 DOI: 10.1002/acg2.54

LaQuisa Hill, Premal Lulla, Helen E Heslop

{"title":"CAR-T cell therapy for non-Hodgkin lymphomas: A new treatment paradigm","authors":"LaQuisa Hill, Premal Lulla, Helen E Heslop","doi":"10.1002/acg2.54","DOIUrl":"10.1002/acg2.54","url":null,"abstract":"The majority of patients with B-cell non-Hodgkin lymphoma (NHL) can be cured with standard chemoimmunotherapy. However, patients who fail first line therapy have dismal outcomes, particularly if they have disease that is resistant to salvage therapy, including chemoimmunotherapy, radiation and/or autologous stem cell transplantation. Indolent B-NHLs, such as follicular lymphoma (FL), although not generally considered curable may be treated over many years with good prognosis. However, a subset of indolent B-NHLs can undergo histologic transformation into more aggressive subtypes with outcomes similar to aggressive B-NHLs. In recent years, T cells, genetically modified with chimeric antigen receptors, have demonstrated a remarkable capacity to induce complete and durable clinical responses in patients with chemotherapy-refractory lymphomas. Indeed, two autologous CD19-directed CAR-modified T-cell products have now been FDA-approved for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma and transformed FL, while a plethora of other CAR-T cell targets are being explored in ongoing clinical trials. The purpose of this review is to summarize the clinical efficacy and unique toxicities of individually developed CAR-T cell products for the treatment of lymphomas, and their evolution from the laboratory bench to commercialization.","PeriodicalId":72084,"journal":{"name":"Advances in cell and gene therapy","volume":"2 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/acg2.54","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43611629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Advances in the treatment of chronic graft-versus-host disease 慢性移植物抗宿主病的治疗进展

Advances in cell and gene therapy Pub Date : 2019-03-28 DOI: 10.1002/acg2.55

Eric D. Johnson, Daniel R. Couriel

引用次数: 0

Advances in CMV infection prevention and treatment after allo-HSCT 同种异体造血干细胞移植后巨细胞病毒感染的预防和治疗进展

Advances in cell and gene therapy Pub Date : 2019-03-18 DOI: 10.1002/acg2.53

Corrado Girmenia

{"title":"Advances in CMV infection prevention and treatment after allo-HSCT","authors":"Corrado Girmenia","doi":"10.1002/acg2.53","DOIUrl":"10.1002/acg2.53","url":null,"abstract":"Cytomegalovirus (CMV) remains a major cause of morbidity and mortality in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Despite this knowledge, a number of CMV-related diagnostic and therapeutic issues remain critical. No uniform guidance exists for the best strategy to monitor and prevent CMV infection and disease. In particular, we lack standard threshold values for assessing the CMV DNAemia in the monitoring of CMV infection; there is no consensus in the adoption of immunoglobulin therapy and adoptive transfer of HSCT donor-derived CMV-specific T cells. Furthermore, antiviral drugs used in the preemptive therapy are characterized by high levels of toxicity. Of interest, recent availability of new drugs will probably modify the antiviral strategy in a large proportion of patients. The uncertainty in the management of CMV infections is further complicated by the continuous evolution in the transplantation strategies and the consequent infectious risk. This paper will focus on challenging issues in the monitoring, prevention, and treatment of CMV infections in allo-HSCT populations. Assessment of pretransplant CMV status, immunological monitoring after transplant, and CMV disease prevention and therapy strategies will be discussed.","PeriodicalId":72084,"journal":{"name":"Advances in cell and gene therapy","volume":"2 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/acg2.53","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48147921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in drug-based therapies in chronic lymphocytic leukemia and future prospects 药物治疗慢性淋巴细胞白血病的进展及前景

Advances in cell and gene therapy Pub Date : 2019-02-08 DOI: 10.1002/acg2.51

Jennifer L. Crombie, Jennifer R. Brown

引用次数: 0

Case report: Impact of BITE on CAR-T cell expansion 病例报告:BITE对CAR - T细胞扩增的影响

Advances in cell and gene therapy Pub Date : 2019-02-04 DOI: 10.1002/acg2.50

Haneen Shalabi, Ashley Koegel, Anusha Ponduri, Haiying Qin, Dalia Salem, Maryalice Stetler-Stevenson, Constance Yuan, Bonnie Yates, Cindy Delbrook, Mignon Loh, Terry J. Fry, Nirali N. Shah

{"title":"Case report: Impact of BITE on CAR-T cell expansion","authors":"Haneen Shalabi, Ashley Koegel, Anusha Ponduri, Haiying Qin, Dalia Salem, Maryalice Stetler-Stevenson, Constance Yuan, Bonnie Yates, Cindy Delbrook, Mignon Loh, Terry J. Fry, Nirali N. Shah","doi":"10.1002/acg2.50","DOIUrl":"10.1002/acg2.50","url":null,"abstract":"Targeted immunotherapeutic approaches have become an attractive, novel therapy in the treatment of chemotherapy resistant or relapsed high-risk acute lymphoblastic leukemia (ALL). Many of these therapies, chimeric antigen receptor (CAR) T cells, and bispecific T-cell engagers (BiTE) in particular, rely on surface expression of the antigen for activity and efficacy. As such, antigen loss is a growing problem in this relapsed population. We present a case of relapsed, refractory B-ALL that has immunophenotypic variability in the leukemia blasts in response to the sequential targeted immunotherapies received. This case additionally describes a bolstered CAR-T cell expansion after the patient received subsequent blinatumomab therapy, suggesting a potential strategy for utilization of multiagent immunotherapies to have synergistic approaches to eradicate disease and prolong remission in patients with relapsed hematologic malignancies (Anti-CD22 chimeric receptor T cells in pediatric and young adult patients with recurrent or relapsed CD22-expressing B-cell malignancies. clinicaltrials.gov NCT02315612).","PeriodicalId":72084,"journal":{"name":"Advances in cell and gene therapy","volume":"2 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/acg2.50","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42960315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

The role of autologous stem cell transplantation in diffuse large B-cell lymphoma 自体干细胞移植在弥漫性大B细胞淋巴瘤中的作用

Advances in cell and gene therapy Pub Date : 2019-01-17 DOI: 10.1002/acg2.33

Liana Nikolaenko, Alex F. Herrera

引用次数: 3

Advances in chronic myelomonocytic leukemia and future prospects: Lessons learned from precision genomics 慢性髓细胞白血病的研究进展及未来展望:精密基因组学的经验教训

Advances in cell and gene therapy Pub Date : 2019-01-16 DOI: 10.1002/acg2.48

Abhishek A. Mangaonkar, Mrinal M. Patnaik

{"title":"Advances in chronic myelomonocytic leukemia and future prospects: Lessons learned from precision genomics","authors":"Abhishek A. Mangaonkar, Mrinal M. Patnaik","doi":"10.1002/acg2.48","DOIUrl":"10.1002/acg2.48","url":null,"abstract":"In the latest World Health Organization classification of myeloid neoplasms, chronic myelomonocytic leukemia (CMML) exists as a separate entity under the category of myelodysplastic/myeloproliferative (MDS/MPN) overlap syndromes. Outcomes remain uniformly poor with a median overall survival of ~2 years and an inherent risk of transformation into acute myeloid leukemia (15%-20% over 5 years). Due to unique biologic characteristics such as overlapping features of myelodysplasia and myeloproliferation, and clinical diversity despite relative genomic homogeneity, CMML represents a unique model to study chronic myeloid tumor biology. Recent advances have focused on understanding the role of putative genomic abnormalities, in particular, clonal evolution of pathogenic alterations in genes regulating the epigenome (TET2), chromatin architecture (ASXL1), spliceosome complex (SRSF2, SF3B1), and cell signaling (NRAS, KRAS, CBL, JAK2). Disease prognostication has evolved from purely clinical prognostic models to those incorporating pathogenic gene variants. Therapeutic options in this disease remain dismal with only two agents approved by the United States Food and Drug Administration, namely 5-azacitidine and decitabine. Allogeneic hematopoietic stem cell transplantation remains the sole curative option in this disease; however, is associated with substantial treatment-related morbidity and mortality. Future areas of research include opportunities to further improve disease prognostication by employing novel technologies such as machine learning, incorporation of methylation and cytokine signatures, in addition to gene mutations; insights into clonal origins of this disease, and novel therapeutic strategies.","PeriodicalId":72084,"journal":{"name":"Advances in cell and gene therapy","volume":"2 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/acg2.48","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47985794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

The therapeutic role of natural killer cells in multiple myeloma 自然杀伤细胞在多发性骨髓瘤中的治疗作用

Advances in cell and gene therapy Pub Date : 2019-01-16 DOI: 10.1002/acg2.49

Ghulam Rehman Mohyuddin, Muzaffar H. Qazilbash

引用次数: 1